ArticleVascular pharmacology2024

12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection.

Taylor C Kress et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.